Research due to be presented at the American Society of Clinical Oncology (ASCO) Virtual Meeting (29–31 May 2020) suggests that cancer progression in COVID-19 patients is associated with a greater death risk. The findings also report that the combination of hydroxychloroquine and azithromycin – a potential treatment option for COVID-19 – is also associated with an increased risk of death.
The data was obtained from the COVID-19 and Cancer Consortium (CCC19) registry. The registry collects reports of cancer patients who have been diagnosed with COVID-19, it includes data reported by healthcare providers from the United States, Canada, Argentina, the European Union and the United Kingdom.
To view the full article, please register now for access